Conclusions
- A significant proportion of prostate cancer patients undergoing liquid profiling have PARPi-associated HRR variants detected only as CH, especially in ATM and CHEK2.
- These findings identify a clinically meaningful risk of variant misclassification of HRR variants in prostate cancer with plasma-only testing.
- Simultaneous sequencing of matched WBC DNA distinguishes CH-derived HRR variants from actionable HRR variants, informing appropriate patient selection for PARPi therapy.

